Blood Bags Sales Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[235+ Pages Report] According to Facts & Factors, the global Blood Bags Sales market size was estimated at USD 3.15 billion in 2025 and is expected to reach USD 5.85 billion by the end of 2034. The Blood Bags Sales industry is anticipated to grow by a CAGR of 7.1% between 2026 and 2034. The Blood Bags Sales Market is driven by the continuous rise in blood transfusion procedures, growing surgical volumes, expanding voluntary blood donation programs, and increasing prevalence of blood disorders and trauma cases worldwide.

Market Overview

The blood bags sales market comprises specialized, sterile, flexible plastic containers (primarily polyvinyl chloride – PVC – based) used for the safe collection, storage, transportation, processing, and transfusion of whole blood and its components (red cells, plasma, platelets, cryoprecipitate). These bags incorporate integrated tubing systems, anticoagulant/preservative solutions (CPD, CPDA-1, SAGM, etc.), leukocyte reduction filters (in some models), and multiple satellite bags to enable component separation while maintaining closed-system integrity and minimizing bacterial contamination risk. The market serves blood banks, hospitals, transfusion centers, mobile collection units, and plasma fractionation companies, with ongoing emphasis on improving biocompatibility, reducing plasticizer leachables (DEHP migration), enhancing traceability through RFID/barcode integration, and meeting stringent international standards (ISO 3826, WHO guidelines, national pharmacopeia requirements).

Key Insights

• As per the analysis shared by our research analyst, the global Blood Bags Sales market is estimated to grow annually at a CAGR of around 7.1% over the forecast period (2026-2034).
• In terms of revenue, the global Blood Bags Sales market size was valued at around USD 3.15 billion in 2025 and is projected to reach USD 5.85 billion, by 2034.
• The global Blood Bags Sales market is projected to grow at a significant rate due to rising demand for safe blood components driven by increasing surgical volumes, trauma care, oncology treatments, and maternal hemorrhage management.
• Based on the Type, the Triple Blood Bag segment accounted for the largest market share of around 42% in 2025, due to its widespread use for separating whole blood into red cells, plasma, and buffy coat/platelets in most blood banks worldwide.
• Based on the Material, the PVC segment accounted for the largest market share of around 78% in 2025, due to its long-established safety profile, cost-effectiveness, flexibility, and global manufacturing scale despite ongoing DEHP concerns.
• Based on the Application, the Whole Blood Collection segment accounted for the largest market share of around 48% in 2025, due to it being the foundational step in most blood donation workflows before component separation.
• Based on region, Asia Pacific was the leading revenue generator in 2025, with approximately 44% share, due to the world’s largest population, highest number of annual blood collections, rapid expansion of hospital infrastructure, and increasing voluntary donation programs in India and China.

Growth Drivers

• Rising Surgical Volumes and Trauma Care Needs

Global increase in elective surgeries (orthopedic, cardiovascular, oncology), emergency trauma cases, organ transplants, and complicated deliveries creates consistent demand for packed red cells, fresh frozen plasma, platelets, and cryoprecipitate — all of which originate from whole-blood collections using multi-bag systems. Aging populations and rising chronic disease prevalence further amplify transfusion requirements.

Government and NGO-led voluntary blood donation campaigns, coupled with improved donor recruitment and mobile collection units in emerging economies, are steadily increasing annual blood collection volumes — especially in Asia and Africa — directly translating into higher consumption of blood bags and anticoagulant solutions.

Restraints

• Persistent Shortages of Key Raw Materials & Production Capacity

PVC resin, DEHP plasticizer (or alternative plasticizers), and tubing extrusion capacity face periodic supply tightness due to petrochemical volatility, plant shutdowns, and concentration of manufacturing in a limited number of countries (China, India, Europe). This creates allocation challenges during demand spikes (e.g., post-disaster, seasonal dengue outbreaks).

Very low profit margins on standard blood bags, heavy price pressure from government tenders / pooled procurement, and long payment cycles from public-sector buyers discourage investment in capacity expansion and next-generation DEHP-free or RFID-tagged bags in many regions.

Opportunities

• Transition to Non-DEHP / DEHP-Free and BTHC Plasticizers

Growing regulatory and clinical concern over DEHP leachables (endocrine disruption, reproductive toxicity) is accelerating the shift toward alternative plasticizers (TOTM, DINCH, BTHC, Mesamoll) and fully non-PVC materials (polyolefins, EVA). Early adopters can capture premium pricing and preferred-supplier status in high-income markets and forward-looking public tenders.

Integration of RFID/barcode tags, blockchain traceability, and IoT-enabled temperature-logging labels into blood bags opens higher-value opportunities in blood safety, inventory management, and counterfeit prevention — especially in markets moving toward digital transfusion records.

Challenges

• Maintaining Sterility & Quality During Global Supply Disruptions

Blood bags are Class IIb / Class III medical devices requiring stringent aseptic manufacturing, gamma sterilization validation, and extractables/leachables testing. Any disruption in resin supply, tubing extrusion, or sterilization capacity can lead to regional shortages that directly affect blood availability and patient safety.

Balancing cost, safety, and sustainability remains difficult — DEHP-free alternatives are often more expensive and sometimes less flexible or more permeable to gases, while fully recyclable non-PVC options are still in early commercialization stages.

Report Scope

Market Segmentation

The Blood Bags Sales market is segmented by Type, Material, Application, and region.

Based on Type Segment, the Blood Bags Sales market is divided into Single Blood Bag, Double Blood Bag, Triple Blood Bag, Quadruple Blood Bag, and others. The most dominant segment is Triple Blood Bag, which holds the largest share due to its widespread use for separating whole blood into packed red cells, plasma, and buffy coat/platelets in most medium- and large-sized blood banks worldwide; it drives the market by being the workhorse product for component therapy in both developed and developing countries. The second most dominant is Quadruple Blood Bag (with integral leukocyte-reduction filter), growing fastest in high-income markets; this segment contributes significantly to revenue growth due to higher unit price and increasing regulatory preference for pre-storage leukoreduction.

Based on Material Segment, the Blood Bags Sales market is divided into PVC, Non-PVC / DEHP-Free, and others. The most dominant segment is PVC, commanding the highest share because of decades of proven safety data, global manufacturing scale, cost-effectiveness, and flexibility; it propels market expansion by remaining the default material in the vast majority of national blood programs. The second most dominant is Non-PVC / DEHP-Free (polyolefin, EVA, TOTM-plasticized PVC), growing rapidly in premium and regulated markets; this segment advances the market by capturing higher price points and preferred-supplier status in Europe, North America, and forward-looking tenders in Asia.

Based on Application Segment, the Blood Bags Sales market is divided into Whole Blood Collection, Plasma Collection, Platelet Collection, Red Blood Cell Collection, and others. The most dominant segment is Whole Blood Collection, with the largest share owing to it being the entry point for all blood donation workflows; it fuels market growth by generating the highest unit volume across national blood programs. The second most dominant is Platelet Collection (apheresis and pooled buffy-coat methods), growing faster due to rising demand for platelet concentrates in oncology, hematology, and trauma care; this segment supports market development through higher-value multi-bag systems.

Recent Developments

• In early 2025, Terumo BCT received expanded CE mark and FDA clearance for its new generation of DEHP-free quadruple blood bags with inline leukocyte-reduction filter.
• In late 2024, Fresenius Kabi increased production capacity of its CompoGuard® automated blood processing system and associated multi-bag sets in India to serve domestic and export markets.
• In mid-2024, Grifols launched a new RFID-tagged blood bag series in Europe and Latin America to improve traceability from donation to transfusion.

Regional Analysis

• Asia Pacific to dominate the global market

Asia Pacific dominates the global Blood Bags Sales market, driven by the world’s largest annual blood collection volume, highest number of births (requiring neonatal transfusion readiness), fastest-growing hospital bed capacity, and increasing component therapy usage in oncology, thalassemia, and trauma care. India and China together account for the majority of global blood collections and bag consumption. India emerges as the single most dominant country, with the largest national blood transfusion service network, massive voluntary donation drives, and Serum Institute of India + local manufacturers supplying both domestic demand and substantial export volumes to Africa and Southeast Asia.

North America holds the second position, with high per-collection component preparation rates and premium non-PVC / RFID-tagged bag adoption. The United States dominates as the key country, with very high usage of quadruple bags with pre-storage leukoreduction and traceability features, supported by AABB and FDA standards.

Europe maintains a high-value position, driven by near-universal leukoreduction, strong preference for non-DEHP materials, and centralized blood establishment procurement. Germany and France are the leading countries, with Germany benefiting from its domestic manufacturing strength (Fresenius, Macopharma) and France from Établissement Français du Sang’s large-scale standardized purchasing.

Latin America is growing steadily, driven by blood safety improvements and increasing component separation. Brazil dominates as the primary country, with its public blood network (Hemobrás) procuring large volumes of triple and quadruple bags.

The Middle East & Africa region remains fragmented but is expanding in urban centers and trauma care. Egypt and South Africa are the leading countries, with Egypt procuring through government tenders and South Africa using a mix of imported and locally assembled bags.

Competitive Analysis

The global Blood Bags Sales market is dominated by players:

• Terumo Corporation
• Fresenius Kabi AG
• Grifols S.A.
• Haemonetics Corporation
• Macopharma
• JMS Singapore Pte Ltd.
• Neomedic Limited
• Nigale Sichuan Biomedical Co., Ltd.
• Suru International Pvt. Ltd.
• AdvaCare Pharma

The global Blood Bags Sales market is segmented as follows:

By Type

• Single Blood Bag
• Double Blood Bag
• Triple Blood Bag
• Quadruple Blood Bag
• Others

By Material

• PVC
• Non-PVC / DEHP-Free
• Others

By Application

• Whole Blood Collection
• Plasma Collection
• Platelet Collection
• Red Blood Cell Collection
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America